18FDG PET Textural Indices in Adrenal Lesion (ImpactTexture)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03469102|
Recruitment Status : Completed
First Posted : March 19, 2018
Last Update Posted : July 30, 2018
Tumors are characterized by a great heterogeneity. Characterizing this intra-tumor heterogeneity is a major challenge in oncology to improve the therapeutic management and move towards personalized medicine adapted to each patient. However, intra-tumor heterogeneity remains rarely used for diagnostic purposes The discovery of an adrenal mass can occur in different circumstances. Detection of an adrenal mass can be done in a context of secreting syndrome, in the assessment of an extra-adrenal neoplasia or fortuitously when performing an imaging for another reason. The etiologies are numerous (cortical tumors, medullary tumors, metastatic lesion of a extra-adrenal neoplasia, others). The adrenal masses can be divided into two categories, depending on whether they are hyperfunctional or not. In patients without an oncological history, an adrenal mass discovered is most often a benign adenoma, but requires an endocrine assessment. In patients with known primary cancer, approximately 30% of the adrenal masses are malignant.
In all cases, the diagnostic procedure includes an imaging assessment to characterize the lesion and an endocrine assessment. CT scan performed without and after intravenous iodinated contrast agent injection is the first-line examination to assess an adrenal mass.
18F-FDG-PET may be indicated as second-line for characterizing an adrenal mass. Adrenal tumor SUVmax (Standard Uptake Value) and adrenal tumor SUVmax / liver SUVmax ratio are routinely used to determine the malignancy of a lesion. Although very useful for assessing the glucose metabolism of a given lesion, these parameters do not allow assessing the heterogeneity of tumor uptake. The texture analysis corresponds to an analysis of the spatial distribution of FDG uptake, and allows, by the calculation of many indices, an evaluation of the heterogeneity of the tumors.
The hypothesis of our study is that the texture parameters could have an additional diagnostic value to improve the performance of conventional quantitative parameters to determine the malignancy of a lesion.
The objective of this study is to investigate the diagnostic value of texture indices in a large cohort of patients presenting an adrenal lesion
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||53 participants|
|Official Title:||Diagnostic Value of 18FDG PET/CT Textural Indices in Patients With an Adrenal Lesion|
|Actual Study Start Date :||March 1, 2018|
|Actual Primary Completion Date :||July 1, 2018|
|Actual Study Completion Date :||July 27, 2018|
- Diagnostic performance of FDG PET/CT textural indices [ Time Frame: 6 months ]Area Under the Curve
- Cut off value of FDG PET/CT textural indices [ Time Frame: 6 months ]For each cut off value : Sensibility(%)
- Cut off value of FDG PET/CT textural indices [ Time Frame: 6 months ]For each cut off value : Specificity(%)
- Cut off value of FDG PET/CT textural indices [ Time Frame: 6 months ]For each cut off value : Positive and Negative Predictive Value (%),
- Cut off value of FDG PET/CT textural indices [ Time Frame: 6 months ]For each cut off value : Accuracy (%)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03469102
|CHRU de Brest|
|Brest, France, 29609|